Hanson & Doremus Investment Management boosted its holdings in Agilent Technologies, Inc. (NYSE:A – Free Report) by 66.5% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 263 shares of the medical research company’s stock after purchasing an additional 105 shares during the period. Hanson & Doremus Investment Management’s holdings in Agilent Technologies were worth $35,000 at the end of the most recent reporting period.
Other hedge funds have also recently bought and sold shares of the company. McAdam LLC boosted its stake in shares of Agilent Technologies by 3.1% during the 3rd quarter. McAdam LLC now owns 2,531 shares of the medical research company’s stock valued at $376,000 after buying an additional 77 shares during the last quarter. Brown Brothers Harriman & Co. raised its holdings in Agilent Technologies by 13.5% in the third quarter. Brown Brothers Harriman & Co. now owns 646 shares of the medical research company’s stock valued at $96,000 after acquiring an additional 77 shares in the last quarter. Global Retirement Partners LLC boosted its stake in Agilent Technologies by 3.2% during the 3rd quarter. Global Retirement Partners LLC now owns 2,570 shares of the medical research company’s stock valued at $382,000 after acquiring an additional 79 shares during the last quarter. Rovin Capital UT ADV grew its holdings in Agilent Technologies by 1.6% during the 3rd quarter. Rovin Capital UT ADV now owns 5,049 shares of the medical research company’s stock worth $750,000 after acquiring an additional 81 shares in the last quarter. Finally, Marshall Financial Group LLC increased its position in shares of Agilent Technologies by 1.0% in the 3rd quarter. Marshall Financial Group LLC now owns 8,243 shares of the medical research company’s stock worth $1,224,000 after purchasing an additional 82 shares during the last quarter. Institutional investors and hedge funds own 87.42% of the company’s stock.
Insider Buying and Selling
In other news, CEO Padraig Mcdonnell sold 1,911 shares of the stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $150.00, for a total transaction of $286,650.00. Following the transaction, the chief executive officer now owns 39,652 shares in the company, valued at $5,947,800. This represents a 4.60 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 0.33% of the company’s stock.
Agilent Technologies Trading Up 2.9 %
Agilent Technologies (NYSE:A – Get Free Report) last issued its quarterly earnings data on Monday, November 25th. The medical research company reported $1.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.41 by $0.05. Agilent Technologies had a return on equity of 25.43% and a net margin of 19.80%. The business had revenue of $1.70 billion during the quarter, compared to the consensus estimate of $1.67 billion. During the same period in the previous year, the firm posted $1.38 earnings per share. The business’s revenue was up .8% on a year-over-year basis. Sell-side analysts expect that Agilent Technologies, Inc. will post 5.56 earnings per share for the current year.
Agilent Technologies Increases Dividend
The business also recently disclosed a quarterly dividend, which was paid on Wednesday, January 22nd. Shareholders of record on Tuesday, December 31st were issued a dividend of $0.248 per share. This represents a $0.99 annualized dividend and a yield of 0.66%. The ex-dividend date was Tuesday, December 31st. This is an increase from Agilent Technologies’s previous quarterly dividend of $0.24. Agilent Technologies’s payout ratio is presently 22.40%.
Analyst Upgrades and Downgrades
A number of research firms recently commented on A. StockNews.com upgraded Agilent Technologies from a “hold” rating to a “buy” rating in a research note on Tuesday, December 24th. Sanford C. Bernstein decreased their target price on Agilent Technologies from $140.00 to $135.00 and set a “market perform” rating for the company in a research report on Tuesday, November 26th. Barclays lowered their price target on Agilent Technologies from $145.00 to $135.00 and set an “underweight” rating for the company in a report on Wednesday, November 27th. Wells Fargo & Company reduced their price objective on Agilent Technologies from $157.00 to $155.00 and set an “overweight” rating on the stock in a research note on Monday, December 9th. Finally, JPMorgan Chase & Co. lowered their target price on shares of Agilent Technologies from $165.00 to $160.00 and set an “overweight” rating for the company in a research note on Tuesday, November 26th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, Agilent Technologies has a consensus rating of “Hold” and an average target price of $143.62.
Get Our Latest Research Report on Agilent Technologies
About Agilent Technologies
Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.
Read More
- Five stocks we like better than Agilent Technologies
- The Most Important Warren Buffett Stock for Investors: His Own
- How Growth Investors Find High-Growth Stocks and Maximize Returns
- Stock Dividend Cuts Happen Are You Ready?
- Meta’s AI & Smart Glasses Could Drive 20%+ Upside in 2025
- What Are Dividend Challengers?
- NVIDIA’s Slide Continues: Can Retail Investors Stop the Fall?
Want to see what other hedge funds are holding A? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agilent Technologies, Inc. (NYSE:A – Free Report).
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.